Articles

The Omnipod Dash™ device approved for commercialization and release in the U.S. by mid-2018.

Addition of glucagon prevents exercise-induced hypoglycemia.

Guest Post by David Kliff, Editor, Diabetic Investor

With each passing day, it’s becoming more apparent that CGM will replace BGM as the standard for glucose measurement. CGM systems are becoming more patient-friendly, i.e. no calibrations, simple insertion, and cheaper too. The data provided by CGM is transformative, leading to improved outcomes. It is no longer a question of if this will happen but when this will happen.

Researchers discover safe and effective therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset type 1.

Drug shown to reduce risk of CV death or hospitalization for heart failure in adults with CV disease and type 2 diabetes, irrespective of their CV risk at study start.

According to new study, African Americans with type 2 diabetes mellitus (T2DM) have a higher risk of developing pancreatic cancer relative to other ethnic groups.

Researchers seek to determine if implementing process in the ambulatory setting could reducing hospitalization, use of emergency departments.

Research suggests racial/ethnic background can also play a role in increased risk of diagnosis.

While there are a number of factors that can negatively impact adherence to self-care in a person with diabetes, this article will focus on diabetes and alcohol: specifically, on how alcohol consumption limits this adherence and affects the overall health of people with diabetes.

Key ADA poster summaries include liraglutide in type 1 diabetes, oral semaglutide, bottled water's association with type 2 diabetes, & SGLT-2 combo LIK066.